X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Niyad (a lyophilized formulation of nafamostat), an investigational broad-spectrum serine protease inhibitor with anticoagulant, anti-inflammatory, mucus clearing and potential anti-viral activities, towards an FDA approval.
Lead Product(s): Nafamostat
Therapeutic Area: Hematology Product Name: Niyad
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2023
Details:
The net proceeds will be used to advance Niyad (nafamostat), an investigational broad-spectrum serine protease inhibitor with anticoagulant, anti-inflammatory, mucus clearing and potential anti-viral activities, towards an FDA approval.
Lead Product(s): Nafamostat
Therapeutic Area: Hematology Product Name: Niyad
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $26.3 million Upfront Cash: Undisclosed
Deal Type: Private Placement July 21, 2023
Details:
Under the divestment, Alora will accelerate the commercialization of Dsuvia (sufentanil), a synthetic opioid analgesic formulation for the management of acute pain.
Lead Product(s): Sufentanil Citrate
Therapeutic Area: Neurology Product Name: Dsuvia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alora Pharmaceuticals
Deal Size: $2.7 million Upfront Cash: Undisclosed
Deal Type: Divestment April 05, 2023
Details:
The divestment allows AcelRx to participate in the long-term value expected to be created by Alora as they expand the commercialization of Dsuvia (sufentanil citrate).
Lead Product(s): Sufentanil Citrate
Therapeutic Area: Neurology Product Name: Dsuvia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alora Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Divestment March 14, 2023
Details:
DSUVIA (sufentanil), an opioid analgesic, is indicated for use in adults for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Lead Product(s): Sufentanil Citrate
Therapeutic Area: Neurology Product Name: Dsuvia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2022
Details:
DZUVEO® (sufentanil sublingual tablet, 30 mcg), a novel sublingual approach to acute pain management, was designed to provide rapid analgesia via a non-invasive route and to eliminate high peak plasma levels and provide longer duration of action.
Lead Product(s): Sufentanil Citrate
Therapeutic Area: Neurology Product Name: Dzuveo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
Dsuvia (sufentanil) is an opioid analgesic previously only marketed for IV and epidural anesthesia and analgesia, is indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Lead Product(s): Sufentanil Citrate
Therapeutic Area: Neurology Product Name: Dsuvia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
DSUVIA, known as DZUVEO (sufentanil citrate) in Europe, is indicated for use in adults in certified medically supervised healthcare settings, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Lead Product(s): Sufentanil Citrate
Therapeutic Area: Neurology Product Name: Dsuvia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2022
Details:
DSUVIA (sufentanil sublingual tablet), known as DZUVEO® in Europe, is indicated for use in adultsfor the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Lead Product(s): Sufentanil Citrate
Therapeutic Area: Neurology Product Name: Dsuvia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2022
Details:
Study found that Dzuveo (Sufentanil Citrate) lowered the opioid dose required by patients in the post-anesthesia care unit (PACU) by more than five-fold compared to standard intravenous opioid administration.
Lead Product(s): Sufentanil Citrate
Therapeutic Area: Neurology Product Name: Dzuveo
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
